Skip to main content

Table 2 Parameters used in the study, children ≥ 5 years and adults

From: Strict adherence to malaria rapid test results might lead to a neglect of other dangerous diseases: a cost benefit analysis from Burkina Faso

EPIDEMIOLOGICAL PARAMETERS

 

Source1

Malaria attributable fevers (MAF)/febrile patients (dry season)

1.7%

Primary

Malaria attributable fevers (MAF)/febrile patients (rainy season)

25.1%

Primary

Malaria parasite density > 40,000/μL (both seasons)

36.8%

Primary

Death rate treated MAF, high parasite density

0.0%

Primary

Excess death rate untreated MAF, high parasite density

0.4%

Assumption

Excess death rate untreated MAF low parasite density

0.0%

Assumption

Excess death rate untreated MAF in RDT neg

0.0%

Assumption

Death rate treated NMFI

0.84%

Primary

Proportion of potentially fatal non malarial fever (PFNM)

20%

Assumption

Excess death rate untreated PFNM

7%

Assumption

CASE MANAGEMENT, PRESUMPTIVE BRANCH, ADULTS

  

Anti-malarial treatment among MAF

97%

Primary

Anti-malarial treatment among MAF, high parasite density

97.3%

Primary

Anti-malarial treatment among MAF, low parasite density

97%

Assumption

Anti-malarial treatment among those treated with antibiotics

79.3%

Primary

Anti-malarial treatment among those not treated with antibiotics

94.8%

Primary

Antibiotic treatment among NMFI

56.1%

Primary

Antibiotic treatment among PFMN

90%

Assumption

Antibiotic treatment among patients presumptively treated for malaria

47.1%

Primary

Antibiotic treatment among PFMN presumptively treated for malaria

86%

Assumption

Antibiotic treatment among patients not presumptively treated for malaria

80.8%

Primary

Antibiotic treatment among PFMN not treated for malaria

99%

Assumption

CASE MANAGEMENT, RDT, ADULTS

  

Anti-malarial treatment among RDT+, high parasite density (hpd)

100%

Primary

Anti-malarial treatment among RDT+, low parasite density (lpd)

96.4%

Primary

Anti-malarial treatment among RDT-

10%

Assumption

Antibiotic treatment among RDT+

42.5%

Primary

Antibiotic treatment among PFNM RDT+

86%

Assumption

Antibiotic treatment among RDT-

77.4%

Assumption

Antibiotic treatment among PFNM RDT-

98.6%

Assumption

RDT ACCURACY, ADULTS

  

RDT sensitivity, malaria attributable fever (MAF), lpd, dry season

91.6%

Primary

RDT specificity, malaria attributable fever (MAF), dry season

78.7%

Primary

RDT sensitivity, malaria attributable fever (MAF), lpd, rainy season

95.3%

Primary

RDT specificity, malaria attributable fever (MAF), rainy season

77.4%

Primary

RDT sensitivity, MAF, high parasite density

99%

Primary

COSTS, ADULTS

  

Cost of RDT

0.71

(ref. 26)

Cost of anti-malarial treatment, Coartem (average, €)

2

(ref. 26)

Cost of antibiotic treatment (average, €)

0.4

Estimate

Life Value (€) corresponding to 25 US $*YLL

525

(see text)

Life Value (€) corresponding to 150 US $*YLL

3150

(see text)

  1. 1 Primary data obtained from previous RCT (ref. 15) and from previous assessment of the RDT accuracy (ref. 14); assumptions based on estimates from primary data, expert opinion and previous literature (see explanation in text)